A study found another potential benefit of the weight loss drugs: lowered risk of chronic conditions.
GLP-1 agonist medications such as Ozempic and Wegovy are in high demand, largely due to their effectiveness at assisting weight loss. According to a recent study in JAMA, these medications may also reduce the risk for developing certain obesity-related cancers.More evidence suggests that medications such as Ozempic and Mounjaro, originally developed for diabetes and then approved for obesity, have benefits that go beyond these conditions.
“This study mainly adds to the growing body of evidence that supports all these different beneficial effects of GLP-1 receptor agonists,” Wang says. “For patients and clinicians, we want to encourage them both to consider this potential added benefit of cancer prevention when they’re selecting treatments for type 2 diabetes management, especially for patients who are at a higher risk for developing these cancers.
A reduced risk for stomach cancer was also seen but was not statistically significant. The results did not show any difference in risk for thyroid cancer or for post-menopause breast cancer. In addition, only 37 percent of the patients were overweight or had obesity, so it would be helpful to see comparisons in cancer risk only in those patients, he says. “You have to be very careful before you highlight that this is another benefit,” Murphy adds.
“It makes us feel a little bit more comfortable in terms of the safety of GLP-1 class because it’s looking at such a wide population over a really long time,” Poddar says. “There is a lot of stigma around these medications and staying on them for a long time,” especially among patients with obesity, she says, “so it’s very reassuring that the numbers aren’t going the opposite direction.
Insulin resistance—when the body struggles to take up sugar from the blood, leading to the development of type 2 diabetes—drives cancer-causing dysfunctional fat tissue, and GLP-1 drugs also help reduce insulin resistance, saysAnother way GLP-1 drugs may help reduce cancer risk is in the way they can change patients’ eating behaviors, Montour says. Many people taking GLP-1 drugs feel unwell after eating more highly processed foods or higher carbohydrate foods.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic, Mounjaro users turning to protein shakes to help beef up musclesOzempic and Mounjaro users are increasingly turning to protein drinks as a convenient way to supplement protein consumption and combat excess muscle loss.
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsPeople taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
Read more »
Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world useIn the first head-to-head comparison of two blockbuster drugs, patients taking Mounjaro lost more weight than those taking Ozempic.
Read more »
Ozempic vs. Mounjaro: New study reveals which is better to combat obesityBeyond Traditional Diet Pills: Groundbreaking New Weight Loss Drug Is More Effective Than Current Treatments
Read more »
Study finds Mounjaro 'significantly more' effective than Ozempic for weight lossOverweight and obese adults using popular diabetes medications to suppress their appetites are 'significantly more likely' to shed pounds with Eli Lilly's Mounjaro than with Novo Nordisk's Ozempic, a new study has found, a result that could have major implications for one of the hottest new markets in the pharmaceutical field.
Read more »
Mounjaro leads to significantly more weight loss than Ozempic, study suggestsWith more people using drugs like Ozempic and Wegovy for weight loss, food companies are paying close attention and trying to adapt to changing eating habits.
Read more »